INMD vs GMED

For growth investors, Globus Medical, Inc.

(GMED) is the stronger pick with 16. 7% revenue growth year-over-year, versus -6. 2% for InMode Ltd. (INMD). InMode Ltd. (INMD) offers the better valuation at 9. 8x trailing P/E (10. 3x forward), making it the more compelling value choice. Analysts rate Globus Medical, Inc. (GMED) a "Buy" — based on 36 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, InMode Ltd.

(INMD) is the cheapest at 9. 8x versus Globus Medical, Inc. at 19. 9x. On forward P/E, InMode Ltd. is actually cheaper at 10. 3x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Globus Medical, Inc. wins at 0. 54x versus InMode Ltd. 's 1. 04x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Globus Medical, Inc.

(GMED) delivered a total return of +9. 7%, compared to -61. 5% for InMode Ltd. (INMD). Over 10 years, the gap is even starker: GMED returned +233. 8% versus INMD's +105. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), InMode Ltd.

(INMD) is the lower-risk stock at 1. 00β versus Globus Medical, Inc. 's 1. 23β — meaning GMED is approximately 23% more volatile than INMD relative to the S&P 500. On balance sheet safety, InMode Ltd. (INMD) carries a lower debt/equity ratio of 2% versus 3% for Globus Medical, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Globus Medical, Inc.

(GMED) is pulling ahead at 16. 7% versus -6. 2% for InMode Ltd. (INMD). On earnings-per-share growth, the picture is similar: Globus Medical, Inc. grew EPS 422. 7% year-over-year, compared to -36. 4% for InMode Ltd.. Over a 3-year CAGR, GMED leads at 42. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

InMode Ltd.

(INMD) is the more profitable company, earning 25. 3% net margin versus 18. 3% for Globus Medical, Inc. — meaning it keeps 25. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: INMD leads at 23. 0% versus 16. 3% for GMED. At the gross margin level — before operating expenses — INMD leads at 78. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Globus Medical, Inc. (GMED) is the more undervalued stock at a PEG of 0. 54x versus InMode Ltd. 's 1. 04x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, InMode Ltd. (INMD) trades at 10. 3x forward P/E versus 16. 7x for Globus Medical, Inc. — 6. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for GMED: 41. 5% to $110. 29.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, InMode Ltd.

(INMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 00), +105. 6% 10Y return). Both have compounded well over 10 years (INMD: +105. 6%, GMED: +233. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: INMD is a small-cap deep-value stock; GMED is a mid-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.